BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16164742)

  • 21. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
    Patel T; Gupta A; Shah M
    J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of change in tumor stiffness measured by acoustic radiation force impulse imaging for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Mahadevan GSV; Chakkalakkoombil SV; Kayal S; Dharanipragada K; Toi PC; Ananthakrishnan R
    J Clin Ultrasound; 2022 Jun; 50(5):666-674. PubMed ID: 35353384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
    Xiong Y; Liang LZ; Cao LP; Min Z; Liu JH
    Gynecol Oncol; 2011 Oct; 123(1):99-104. PubMed ID: 21741694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer.
    Tewari M; Pradhan S; Singh U; Singh TB; Shukla HS
    Asian J Surg; 2010 Oct; 33(4):157-67. PubMed ID: 21377101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
    Sergieva SB; Timcheva KV; Hadjiolov ND
    J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
    Chatterjee S; Saha A; Arun I; Nayak SS; Sinha S; Agrawal S; Parihar M; Ahmed R
    Breast Cancer (Dove Med Press); 2015; 7():381-8. PubMed ID: 26677343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
    Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
    J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.
    Koh EH; Chung HC; Lee KB; Lim HY; Kim JH; Roh JK; Min JS; Lee KS; Kim BS
    Yonsei Med J; 1992 Jun; 33(2):137-42. PubMed ID: 1357834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous changes of magnetic resonance diffusion-weighted imaging and pathological microstructure in locally advanced cervical cancer caused by neoadjuvant chemotherapy.
    Fu C; Feng X; Bian D; Zhao Y; Fang X; Du W; Wang L; Wang X
    J Magn Reson Imaging; 2015 Aug; 42(2):427-35. PubMed ID: 25328994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy.
    Jakabova A; Bielcikova Z; Pospisilova E; Petruzelka L; Blasiak P; Bobek V; Kolostova K
    Ther Adv Med Oncol; 2021; 13():17588359211028492. PubMed ID: 34345252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI).
    Danishad KK; Sharma U; Sah RG; Seenu V; Parshad R; Jagannathan NR
    NMR Biomed; 2010 Apr; 23(3):233-41. PubMed ID: 20175134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    George J; Dharanipragada K; Krishnamachari S; Chandrasekaran A; Sam SS; Sunder E
    Clin Breast Cancer; 2009 Aug; 9(3):161-5. PubMed ID: 19661039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.
    Datta NR; Rajkumar A; Basu R
    Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Sharma U; Danishad KK; Seenu V; Jagannathan NR
    NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
    Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
    Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.